How to buy Alexion Pharmaceuticals stock | $177.12

Alexion Pharmaceuticals Inc is a biotechnology business based in the US. Alexion Pharmaceuticals shares (ALXN) are listed on the NASDAQ and all prices are listed in US Dollars. Alexion Pharmaceuticals employs 3,837 staff and has a trailing 12-month revenue of around 0.00.

Alexion Pharmaceuticals stock price (NASDAQ: ALXN)

Use our graph to track the performance of ALXN stocks over time.

Alexion Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-09-19.

Latest market close	$177.12
52-week range	$112.27 - $187.45
50-day moving average	$182.75
200-day moving average	$165.77
Wall St. target price	$177.36
PE ratio	59.234
Dividend yield	N/A (0%)
Earnings per share (TTM)	$3.08

Buy Alexion Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Alexion Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alexion Pharmaceuticals price performance over time

Historical closes compared with the close of $177.12 from 2021-06-04

1 week (2021-10-12)	N/A
1 month (2021-09-19)	N/A
3 months (2021-07-21)	-2.95%
6 months (2021-04-23)	6.11%

1 year (2020-10-23)	45.65%
2 years (2019-10-23)	66.11%
3 years (2018-10-23)	44.00%
5 years (2016-10-21)	47.28%

Is Alexion Pharmaceuticals under- or over-valued?

Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Alexion Pharmaceuticals's P/E ratio

Alexion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Alexion Pharmaceuticals shares trade at around 59x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Alexion Pharmaceuticals's PEG ratio

Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1706. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Alexion Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Alexion Pharmaceuticals's EBITDA

Alexion Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.

The EBITDA is a measure of a Alexion Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Alexion Pharmaceuticals financials

Revenue TTM	$6.3 billion
Operating margin TTM	47.41%
Gross profit TTM	$5.5 billion
Return on assets TTM	10.08%
Return on equity TTM	4.43%
Profit margin	10.89%
Book value	$56.21
Market capitalisation	$40.3 billion

TTM: trailing 12 months

Shorting Alexion Pharmaceuticals shares

There are currently 9.8 million Alexion Pharmaceuticals shares held short by investors – that's known as Alexion Pharmaceuticals's "short interest". This figure is 14.6% up from 8.6 million last month.

There are a few different ways that this level of interest in shorting Alexion Pharmaceuticals shares can be evaluated.

Alexion Pharmaceuticals's "short interest ratio" (SIR)

Alexion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alexion Pharmaceuticals shares currently shorted divided by the average quantity of Alexion Pharmaceuticals shares traded daily (recently around 1.8 million). Alexion Pharmaceuticals's SIR currently stands at 5.36. In other words for every 100,000 Alexion Pharmaceuticals shares traded daily on the market, roughly 5360 shares are currently held short.

However Alexion Pharmaceuticals's short interest can also be evaluated against the total number of Alexion Pharmaceuticals shares, or, against the total number of tradable Alexion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alexion Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Alexion Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0444% of the tradable shares (for every 100,000 tradable Alexion Pharmaceuticals shares, roughly 44 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alexion Pharmaceuticals.

Find out more about how you can short Alexion Pharmaceuticals stock.

Alexion Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alexion Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Alexion Pharmaceuticals's total ESG risk score

Total ESG risk: 28.21

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alexion Pharmaceuticals's overall score of 28.21 (as at 12/31/2018) is pretty good – landing it in it in the 26th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Alexion Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Alexion Pharmaceuticals's environmental score

Environmental score: 8.12/100

Alexion Pharmaceuticals's environmental score of 8.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Alexion Pharmaceuticals's social score

Social score: 17.78/100

Alexion Pharmaceuticals's social score of 17.78 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Alexion Pharmaceuticals's governance score

Governance score: 15.31/100

Alexion Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Alexion Pharmaceuticals's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Alexion Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Alexion Pharmaceuticals has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Alexion Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.

Total ESG score	28.21
Total ESG percentile	26.48
Environmental score	8.12
Environmental score percentile	9
Social score	17.78
Social score percentile	9
Governance score	15.31
Governance score percentile	9
Level of controversy	2

Alexion Pharmaceuticals share dividends

We're not expecting Alexion Pharmaceuticals to pay a dividend over the next 12 months.

Have Alexion Pharmaceuticals's shares ever split?

Alexion Pharmaceuticals's shares were split on a 2:1 basis on 22 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alexion Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alexion Pharmaceuticals shares which in turn could have impacted Alexion Pharmaceuticals's share price.

Alexion Pharmaceuticals share price volatility

Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $112.27 up to $187.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alexion Pharmaceuticals's is 1.2595. This would suggest that Alexion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alexion Pharmaceuticals overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally.

Frequently asked questions

What percentage of Alexion Pharmaceuticals is owned by insiders or institutions?
Currently 0.268% of Alexion Pharmaceuticals shares are held by insiders and 88.023% by institutions. How many people work for Alexion Pharmaceuticals?
Latest data suggests 3,837 work at Alexion Pharmaceuticals. When does the fiscal year end for Alexion Pharmaceuticals?
Alexion Pharmaceuticals's fiscal year ends in December. Where is Alexion Pharmaceuticals based?
Alexion Pharmaceuticals's address is: 121 Seaport Boulevard, Boston, MA, United States, 02210 What is Alexion Pharmaceuticals's ISIN number?
Alexion Pharmaceuticals's international securities identification number is: US0153511094 What is Alexion Pharmaceuticals's CUSIP number?
Alexion Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 015351109